Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SLS Stock Forecast 2026-2027
$5.03
Current Price
$903.30M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SLS Price Targets
+98.8%
To High Target of $10.00
+98.8%
To Median Target of $10.00
+19.3%
To Low Target of $6.00
SLS Price Momentum
+2.4%
1 Week Change
+5.7%
1 Month Change
+289.9%
1 Year Change
+33.4%
Year-to-Date Change
-18.1%
From 52W High of $6.14
+299.2%
From 52W Low of $1.26
📊 TOP ANALYST CALLS
Did SLS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if SELLAS is one of their latest high-conviction picks.
Latest SLS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, SLS has a bullish consensus with a median price target of $10.00 (ranging from $6.00 to $10.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $5.03, the median forecast implies a 98.8% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason McCarthy at Maxim Group, projecting a 98.8% upside. Conversely, the most conservative target is provided by Li Watsek at Cantor Fitzgerald, suggesting a 19.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SLS Analyst Ratings
3
Buy
0
Hold
0
Sell
SLS Price Target Range
Low
$6.00
Average
$10.00
High
$10.00
Current: $5.03
Latest SLS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SLS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | Jason McCarthy | Buy | Maintains | $10.00 |
| Jul 16, 2025 | Maxim Group | Jason McCarthy | Buy | Maintains | $7.00 |
| Nov 22, 2023 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $3.00 |
| Sep 7, 2023 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $3.00 |
| Nov 15, 2022 | Alliance Global Partners | James Molloy | Buy | Maintains | $8.00 |
| Jun 28, 2022 | Cantor Fitzgerald | Li Watsek | Overweight | Maintains | $6.00 |
| Jul 21, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 18, 2019 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Nov 18, 2019 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Nov 18, 2019 | Oppenheimer | Outperform | Initiates | $N/A | |
| Nov 18, 2019 | Maxim Group | Buy | Upgrade | $N/A | |
| Nov 15, 2019 | Maxim Group | Buy | Upgrade | $N/A | |
| Apr 8, 2019 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Nov 1, 2018 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jul 20, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $5.00 |
| Apr 2, 2018 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Apr 2, 2018 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Mar 19, 2018 | Maxim Group | Buy | Upgrade | $N/A |
Sellas Life Sciences Group Inc. (SLS) Competitors
The following stocks are similar to SELLAS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sellas Life Sciences Group Inc. (SLS) Financial Data
Sellas Life Sciences Group Inc. has a market capitalization of $903.30M with a P/E ratio of -20.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -66.9%.
Valuation Metrics
Market Cap
$903.30M
Enterprise Value
$866.63M
P/E Ratio
-20.1x
PEG Ratio
-27.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+8.0%
Current Ratio
10.7x
Debt/Equity
1.4x
ROE
-66.9%
ROA
-34.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sellas Life Sciences Group Inc. (SLS) Business Model
About Sellas Life Sciences Group Inc.
What They Do
Develops novel cancer therapeutics and immunotherapies.
Business Model
The company operates as a late-stage clinical biopharmaceutical firm focused on developing innovative cancer treatments. It generates revenue through strategic partnerships and collaborations with major pharmaceutical companies, conducting clinical trials, and potentially commercializing its therapies once they receive regulatory approval.
Additional Information
Sellas Life Sciences was founded in 2012 and is based in New York. Its lead product, galinpepimut-S, is currently being tested in collaboration with Merck & Co. for enhanced efficacy in cancer therapy, while its second product, SLS009, is positioned to target specific cancer treatment opportunities. The company aims to address significant unmet medical needs in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Country
United States
IPO Year
2008
Website
sellaslifesciences.comSellas Life Sciences Group Inc. (SLS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet
The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Apr 20, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
These 16 stocks are a short seller's dream — likely losers no matter what the market does
26 days ago
Quick Summary
Borrowing costs are impacting trading profits, making certain stocks cheaper to short. Investors may find opportunities in these lower-cost short positions.
Why It Matters
Rising borrowing costs reduce trading profits, making shorting stocks more appealing and potentially volatile, impacting stock valuations and investor strategies.
Source: Market Watch
Market Sentiment:
Negative
Quick Summary
SELLAS Life Sciences Group, Inc. (SLS) has a consensus price target indicating a 63.6% upside potential, with recent upward revisions in earnings estimates suggesting possible near-term gains.
Why It Matters
The 63.6% upside potential suggests significant growth for SELLAS Life Sciences, while rising earnings estimates indicate momentum, potentially attracting investors looking for gains.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
SELLAS Life Sciences Group, Inc. (SLS) has received a Zacks Rank #2 (Buy) upgrade, indicating improved earnings outlook, which may positively impact the stock price.
Why It Matters
SELLAS Life Sciences' upgrade to Zacks Rank #2 signals improved earnings expectations, potentially boosting stock demand and price in the short term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
SELLAS Life Sciences Group (NASDAQ: SLS), a late-stage biopharmaceutical firm, is experiencing a significant inflection point in its focus on cancer immunotherapy.
Why It Matters
SELLAS Life Sciences Group's progress in late-stage clinical trials may signal potential breakthroughs in cancer treatment, impacting stock performance and investor sentiment in the biopharma sector.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
The Phase 3 REGAL Trial of Galinpepimut-S (GPS) for Acute Myeloid Leukemia (AML) is advancing, with a final analysis planned upon reaching 80 events.
Why It Matters
The progress of the REGAL Trial indicates potential advancements in AML treatment, which could lead to market approval and increase the company's valuation, impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Preclinical data indicate that SLS009 effectively reduces the apoptotic threshold in AML cells by inhibiting key survival pathways.
Why It Matters
Positive preclinical data for SLS009 in AML indicates potential for effective treatment, which can boost the company's stock value and attract investment in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SLS Stock
What is Sellas Life Sciences Group Inc.'s (SLS) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Sellas Life Sciences Group Inc. (SLS) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $6.00.
Is SLS stock a good investment in 2026?
According to current analyst ratings, SLS has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SLS stock?
Wall Street analysts predict SLS stock could reach $10.00 in the next 12 months. This represents a 98.8% increase from the current price of $5.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sellas Life Sciences Group Inc.'s business model?
The company operates as a late-stage clinical biopharmaceutical firm focused on developing innovative cancer treatments. It generates revenue through strategic partnerships and collaborations with major pharmaceutical companies, conducting clinical trials, and potentially commercializing its therapies once they receive regulatory approval.
What is the highest forecasted price for SLS Sellas Life Sciences Group Inc.?
The highest price target for SLS is $10.00 from Jason McCarthy at Maxim Group, which represents a 98.8% increase from the current price of $5.03.
What is the lowest forecasted price for SLS Sellas Life Sciences Group Inc.?
The lowest price target for SLS is $6.00 from Li Watsek at Cantor Fitzgerald, which represents a 19.3% increase from the current price of $5.03.
What is the overall SLS consensus from analysts for Sellas Life Sciences Group Inc.?
The overall analyst consensus for SLS is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are SLS stock price projections?
Stock price projections, including those for Sellas Life Sciences Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:49 AM UTC